Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2024-01-23 Regulatory Filings
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 94% confidence The document is an announcement titled "Publication of ACTIMIS clinical study results in the Lancet Neurology Journal." It details the achievement of primary endpoints, safety confirmation, and specific efficacy results from a clinical trial (ACTIMIS) for the drug glenzocimab. It explicitly states that the full analysis is displayed in the manuscript published in *The Lancet Neurology Journal* and provides a link to that paper. Since this document is an announcement *about* the publication of detailed results (the actual scientific paper), and it is not a general regulatory filing (RNS) or a standard earnings release (ER), it best fits the category for announcements related to specific company activities or data releases that aren't standard financial reports. However, given the options, this is a highly specific announcement of scientific/clinical data. It is not a standard financial report (10-K, IR, ER, MRQ). It is not a presentation (IP) or a management discussion (MDA). It is an announcement of a major data release. Since there is no specific 'Clinical Trial Result Announcement' code, we must evaluate the closest fit. It is not a Report Publication Announcement (RPA) because it contains the core results, not just a notice that a report is available. It is not a Legal Report (LTR). It is a detailed announcement of scientific findings. In the context of financial filings, major scientific data releases often accompany or are summarized in Investor Presentations (IP) or are treated as significant Regulatory Filings (RNS) if they impact valuation. Given the depth of the results provided, it is more than just a brief update. However, if we strictly follow the definitions, this is a detailed announcement of clinical data, which often serves as the basis for an Investor Presentation or is released via RNS. Since it is a press release announcing the publication of study results, and it is not a standard financial report, RNS (Regulatory Filings) is the most appropriate general category for significant, non-standard corporate news releases that don't fit elsewhere. If 'IP' (Investor Presentation) were meant to cover all investor-facing data releases, it might fit, but 'IP' usually implies a slide deck. RNS serves as the best catch-all for significant, non-standard corporate news like this.
2024-01-23 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated January 23, 2024, announcing the publication of clinical study results (ACTIMIS trial for glenzocimab) in the medical journal *The Lancet Neurology*. It details key safety and efficacy findings, quotes management and the principal investigator, and provides context about ongoing and future trials (ACTISAVE). This type of announcement, which disseminates significant scientific or clinical data outside of a formal regulatory filing like a 10-K or a standard quarterly report, is best classified as an announcement related to research or clinical progress. Since there is no specific category for 'Clinical Trial Result Announcement' or 'Scientific Publication Announcement', and it is not a formal Earnings Release (ER) or a comprehensive Interim Report (IR), it falls under the general category for significant corporate news that doesn't fit elsewhere, which is Regulatory Filings (RNS). It is not a short announcement pointing to an attached report (RPA), as it contains substantial content detailing the results themselves.
2024-01-23 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT WITH THE BROKERAGE FIRM KEPLER CHEUVREUX" and is dated January 17, 2024, reporting data up to December 31, 2023. This clearly indicates it is a periodic financial report covering a six-month period (half-year). This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR), which covers periods shorter than a year. Although it is a specific report on a liquidity contract, its nature as a periodic financial disclosure makes 'IR' the most appropriate classification among the choices, as 'AR' is reserved for the full Annual Report, and 'MRQ' is for major shareholding notifications. It is a full report, not just an announcement of a report (RPA/RNS).
2024-01-17 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled "Disclosure of the total number of voting rights and shares as of December 31, 2023" and explicitly states it is disclosing this information pursuant to French Commercial Code and AMF regulations. It provides a table detailing the number of shares and voting rights as of a specific date (December 31, 2023). This type of mandatory disclosure regarding the total share capital and voting power is a specific regulatory filing requirement, often related to shareholder structure or meeting preparations, but it does not fit perfectly into the primary categories like 10-K, ER, or IR. It is a specific regulatory announcement. While it relates to voting rights, it is a factual disclosure of the current count, not the results of a vote (DVA) or proxy solicitation (PSI). Given the nature of disclosing share capital structure and voting rights, it is best classified as a specific regulatory announcement. Since there isn't a dedicated code for 'Total Voting Rights Disclosure', and it is a formal regulatory communication, the closest fit among the options that covers specific regulatory announcements not covered elsewhere is RNS (Regulatory Filings - general fallback for miscellaneous filings). However, the content is highly specific to share structure and voting rights, which is often a component of proxy/shareholder materials. Reviewing the definitions, DVA is for 'Official results from shareholder votes', which this is not. Since this is a mandatory disclosure of the share base used for voting, and it is a formal press release/communique, RNS is the most appropriate fallback for a specific regulatory disclosure not listed elsewhere.
2024-01-17 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Regulatory Filings Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LA SOCIÉTÉ DE BOURSE KEPLER CHEUVREUX" (Semi-annual statement of the liquidity contract with Kepler Cheuvreux) and is explicitly labeled as a "COMMUNIQUÉ DE PRESSE" (Press Release). It details the status of a liquidity contract (market making/stabilization agreement) as of December 31, 2023, comparing it to the previous statement (June 30, 2023) and the initiation date. This type of periodic report on market stabilization activities is a specific regulatory disclosure, often related to share trading or capital management. It is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). Since it is a specific announcement regarding the status of a financial arrangement (liquidity contract) and is presented as a press release detailing figures, it fits best under a category related to capital/financing updates or a specific regulatory filing. Given the options, this document reports on the activity related to maintaining market liquidity, which is closely tied to share capital management and financing activities. However, the core content is a periodic report on a specific financial arrangement (liquidity contract) mandated by regulatory bodies (AMF mentioned). This is a specialized disclosure. It is not a general regulatory filing (RNS) because it is highly specific. It is not a Capital/Financing Update (CAP) in the sense of raising new funds, but rather managing existing share liquidity. Since the document is a detailed, periodic statement about the liquidity contract, and not just an announcement that a report is available (RPA), it should be classified based on its content. Liquidity contracts are often disclosed under rules pertaining to share transactions or capital maintenance. Given the available codes, 'Transaction in Own Shares' (POS) relates to share buybacks, which is related but not the exact nature of reporting on a liquidity contract. 'Capital/Financing Update' (CAP) is broad enough to cover disclosures related to share market support mechanisms. Alternatively, since it is a specific, periodic regulatory disclosure not covered by other major categories, it could fall under 'Regulatory Filings' (RNS). However, the content is highly specific to share trading activity managed by a third party. Considering the detailed breakdown of transactions and balances related to share support, it is most closely related to share capital management. If we must choose the most specific fit among the options, 'Transaction in Own Shares' (POS) is often used broadly for disclosures involving the company's own shares being traded, even if managed by a third party for stabilization. Given the context of French market disclosures, these liquidity contract reports are highly specific. Since it is a detailed report, not an announcement of a report, and deals with share activity, I will lean towards the most relevant financial activity category. If the document were purely about a dividend or a share issue, those codes would apply. Since it is about market stabilization/liquidity, which involves buying/selling shares, 'POS' (Transaction in Own Shares) is a plausible, though imperfect, fit if a dedicated 'Liquidity Contract Report' code is missing. Given the options, and recognizing this is a periodic report on share activity, I will classify it as a specific regulatory disclosure that doesn't fit the main financial reports, leaning towards RNS as the best general fit for specialized, non-standard reports, or CAP if interpreted as capital maintenance. Given the explicit mention of AMF rules for liquidity contracts, RNS (General regulatory announcements/fallback) is the safest classification for a specialized report not explicitly listed, unless it strongly implies a share repurchase program (POS). Since it details the *contract* status, RNS is appropriate.
2024-01-17 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 décembre 2023" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of December 31, 2023). It explicitly references Article 223-16 of the AMF General Regulation, which governs the disclosure of total voting rights and shares. The content provides a table detailing the total number of shares and voting rights as of a specific date (31/12/2023). This type of mandatory periodic disclosure regarding the capital structure and voting rights is typically classified as a regulatory filing or a specific announcement related to share capital changes, although it is not a standard SEC form. Given the options, this is a specific regulatory disclosure about the share count. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is most closely related to changes in share capital structure, but since it is a mandatory monthly disclosure of the *current* count, and not a transaction (POS) or a major shareholding notification (MRQ) by an external party, it fits best under the general regulatory announcement category, RNS, or potentially a specific capital structure announcement if one were available. However, since it is a formal, periodic disclosure mandated by the regulator (AMF) detailing the total number of shares and voting rights, it is a specific type of regulatory filing. Reviewing the definitions, 'SHA' is for Share Issue/Capital Change, which this is related to, but 'RNS' (Regulatory Filings) is the best general fit for mandatory, non-financial periodic disclosures that don't fit elsewhere, especially when referencing specific local regulatory articles (AMF). Given the precise nature of the data (total shares/votes), it is a specific regulatory disclosure. If we consider the closest fit among the options, it is a notification about the capital structure. Since there isn't a specific 'Total Voting Rights' code, RNS is the most appropriate fallback for a mandatory regulatory disclosure not covered by other specific financial reports or transaction types. However, since it directly reports the total number of shares and voting rights, it is fundamentally a capital structure update. Let's re-evaluate SHA (Share Issue/Capital Change). While it's not an *issue* or *split*, it is a mandatory report on the current state of the capital base. Given the options, RNS is the safest general regulatory classification for this type of periodic AMF filing.
2024-01-17 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.